Related Experiment Video
Updated: Feb 6, 2026

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
Current and emerging therapies in primary myelofibrosis
Sabarish Ayyappan1, Murali Janakiram, Radha Raghupathy
1Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA.
Primary myelofibrosis is a serious blood disorder causing bone marrow fibrosis and poor survival. Emerging targeted therapies, including JAK2 inhibitors, offer new hope for improved patient outcomes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Primary myelofibrosis is a clonal hematopoietic stem cell disorder.
- Characterized by ineffective hematopoiesis, bone marrow fibrosis, and poor prognosis.
- High-risk patients have a median survival of only 2 years.
Purpose of the Study:
- To review recent discoveries in myelofibrosis pathogenesis.
- To focus on emerging targeted treatments for the disease.
- To discuss novel therapies and their potential impact on patient outcomes.
Main Methods:
- Review of scientific literature on myelofibrosis.
- Analysis of genetic mutations, including JAK2 V617F.
- Evaluation of novel therapeutic strategies.
Main Results:
- Discovery of key mutations driving myelofibrosis pathogenesis.
- Identification of novel targeted therapies like JAK2 inhibitors.
- Potential for improved treatment efficacy with new agents.
Conclusions:
- Targeted therapies, including JAK2 inhibitors, show promise.
- Novel treatments may improve outcomes for myelofibrosis patients.
- Further research is needed to optimize combination therapies.
Related Concept Videos
Introduction Cardiac Emergencies
Applications of GIS: Disaster Management and Emergency Response
Emerging Adulthood
Gene Therapy
Electrical Current
Primary and Secondary Growth in Roots and Shoots

